Patients with stage II pancreatic cancer who are treated with chemotherapy followed by resection live nearly twice as long as patients who receive only chemotherapy, according to a recent study published by Amanda K. Arrington, MD, MHM, FACS, and colleagues in the Journal of the American College of Surgeons.
In stage II patients, there is a chance that pancreatic cancer can be removed by resection even after it has spread close to blood vessels. Although chemotherapy can improve outcomes, the risk of surgery is justified because the patients live longer even if the cancerous tissue is not entirely removed, according to the study from researchers at the University of Arizona Department of Surgery, Tucson.
Amanda K. Arrington, MD, MHM, FACS
The researchers found that patients who received chemotherapy followed by resection lived an average of 19.75 months, while those who received only chemotherapy lived an average of 10.12 months. They examined data from the National Cancer Database (NCDB).
“Our results show that surgery is viable in more cases than we thought,” said Dr. Arrington, a surgical oncologist at the University of Arizona Department of Surgery, Tucson.
Survival rates for pancreatic cancer are low because it is a fairly aggressive, fast-growing cancer, Dr. Arrington said. Approximately 10% to 30% of these patients present with disease in which resection may be considered an appropriate therapy. Chemotherapy can improve the chances for successful surgery, as about one in three borderline cases are resectable following chemotherapy, according to research published by Gillen et al in PLOS Medicine. Even after surgery, however, it is common for pancreatic cancer to return.
While the goal of resection is to remove all of the tumor tissue, it can be difficult to accomplish, especially if the cancer has spread to nearby blood vessels that feed the liver and small intestine. Margin status is a significant predictor of survival after surgery for pancreatic cancer. Patients with no cancerous tissue left after resection (R0) have improved survival compared with patients with microscopic amounts (R1) or macroscopic amounts (R2) of cancerous tissue left after resection. This study looked at R1 and R2 resection outcomes compared with chemotherapy alone.
Outcomes With Resection and Chemotherapy
Dr. Arrington and her colleagues searched NCDB data from 2010 to 2015 for patients with stage II pancreatic cancer who underwent R1/R2 surgery with or without presurgical chemotherapy to compare to stage II patients who received chemotherapy alone. They found:
The data were analyzed in multiple ways to address potential bias; all analyses of the data delivered the same findings.
Study results confirm current recommendations for stage II pancreatic cancer, which note that survival improves when patients receive multimodality therapy, chemotherapy before and/or after resection. Further, patients benefit from surgery even in extremely difficult cases that end up with a margin positive resection, said Dr. Arrington. The researchers found even when the tumor does not shrink significantly in response to chemotherapy, there are still survival benefits to taking an aggressive surgical approach.
“Based on this study, surgeons can be a little more aggressive and offer surgical treatment more often than not to [patients with] stage II pancreatic cancer,” concluded Dr. Arrington said. “There are ongoing studies looking at whether more [patients with] pancreatic cancer, including stage I patients, would benefit from surgery after chemotherapy.”
Disclosure: For full disclosures of the study authors, visit journalacs.org.The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.